Pearl Steinzor

Sunil Sharma, MD, discusses the consequences of not diagnosing patients with sleep-disordered breathing during hospital admission.

Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.

Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.

Shields Health Solutions is collaborating with Baptist Health to launch an integrated onsite specialty pharmacy at Baptist MD Anderson Cancer Center.

The FDA approved a supplemental BLA for Organon's tocilizumab biosimilar Tofidence.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

Sandra Chaparro, MD, makes the case for SGLT2 inhibitors across a broad spectrum of chronic kidney disease, even in patients without diabetes.

Orforglipron added to titrated insulin glargine reduced HbA1c at 40 weeks while producing clinically meaningful weight reductions.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

A turbulent regulatory environment is forcing covered entities to rethink how they manage 340B compliance.

Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

Exposure to adverse pregnancy outcomes may be associated with worse cardiovascular health and early arterial injury in young adulthood.

From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.